Assays for BTK inhibitors

US10012650B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10012650-B2
Application numberUS-201514964945-A
CountryUS
Kind codeB2
Filing dateDec 10, 2015
Priority dateDec 11, 2014
Publication dateJul 3, 2018
Grant dateJul 3, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to BTK occupancy assays.

First claim

Opening claim text (preview).

We claim: 1. A method for determining drug target occupancy of a BTK inhibitor compound, comprising: (a) contacting a sample comprising a mixture of BTK kinase and a BTK inhibitor compound, with a probe to form a probe-bound kinase; (b) detecting the amount of probe-bound kinase in the sample; and (c) determining the occupancy of the BTK inhibitor compound based on the amount of probe-bound kinase detected in the sample; wherein the probe is: 2. The method of claim 1 , wherein the step of determining target occupancy comprises determining the number of binding sites not occupied by the BTK kinase inhibitor based on the amount of probe-bound kinase detected in the sample. 3. The method of claim 1 , further comprising a step of determining or modifying a therapeutic regimen based on the target occupancy of the BTK kinase. 4. The method of claim 1 , further comprising a step of performing the method at two or more time points.

Assignees

Inventors

Classifications

  • involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

  • G01N33/53Primary

    Immunoassay; Biospecific binding assay; Materials therefor · CPC title

  • involving labelled substances (G01N33/53 takes precedence) · CPC title

  • Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor) · CPC title

  • transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10012650B2 cover?
The present invention relates to BTK occupancy assays.
Who is the assignee on this patent?
Merck Patent Gmbh
What technology area does this patent fall under?
Primary CPC classification G01N33/53. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Jul 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).